<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00473265</url>
  </required_header>
  <id_info>
    <org_study_id>AAAA5457</org_study_id>
    <secondary_id>R01DK069350</secondary_id>
    <nct_id>NCT00473265</nct_id>
  </id_info>
  <brief_title>Bone Properties in Hypoparathyroidism: Effects of PTH</brief_title>
  <official_title>Bone Properties in Hypoparathyroidism: Effects of PTH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John P. Bilezikian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Whereas much information is known about the properties of bone in primary
      hyperparathyroidism, a disorder of parathyroid hormone (PTH) excess, virtually nothing is
      known about the skeleton in hypoparathyroidism, a disorder in which PTH is absent. The
      purpose of this research project is to test the hypothesis that the skeleton in
      hypoparathyroidism is abnormal in its metabolic, densitometric, geometric, biomechanical and
      microarchitectural features. We will also test the hypothesis that the skeleton is dependent
      upon PTH for normal structure and function. Using non-invasive approaches as well as direct
      analysis of bone itself, the human hypoparathyroid skeleton will be thoroughly characterized.
      With each patient serving as his/her own control, we will determine how, to what extent, and
      in what ways the administration of PTH restores skeletal dynamics and structure to the
      hypoparathyroid skeleton. In this way, we will identify those structural and dynamic elements
      of the skeleton that are influenced by or dependent upon PTH. Methods to be utilized include
      dual energy X-ray absorptiometry, quantitative central and peripheral computed tomography,
      geometry and size quantification, histomorphometry by standard and microCT methods, finite
      element analysis, biochemical bone markers, quantitative back scattered electron imaging, and
      Fourier Transform Infrared Spectroscopy. This research project will extend our knowledge of
      the skeletal effects of PTH to its deficient range and thus complete our understanding of PTH
      action on bone gained by our many years of studying PTH overexpression in primary
      hyperparathyroidism. This investigation may also provide insight into the means by which PTH
      helps to restore the skeleton when it is used to treat osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A detailed description of the methods used in this study include the following: direct
      analysis of bone itself. skeletal dynamics and structure such as dual energy X-ray
      absorptiometry, quantitative central and peripheral computed tomography, geometry and size
      quantification, histomorphometry by standard and microCT methods, finite element analysis,
      biochemical bone markers, quantitative back scattered electron imaging, and Fourier Transform
      Infrared Spectroscopy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Requirements for Calcium Supplementation</measure>
    <time_frame>2 years</time_frame>
    <description>Serum and urinary calcium levels maintained by change in requirements for calcium supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in BMD From Baseline to 24 Months by DXA</measure>
    <time_frame>baseline versus 24 months</time_frame>
    <description>Bone Mineral Density (BMD) as measured by Dual-energy X-ray absorptiometry (DXA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular Width</measure>
    <time_frame>baseline versus two years</time_frame>
    <description>Trabecular width was obtained from histomorphometric assessment of percutaneous iliac crest bone biopsy. Trabecular width is the thickness of individual pieces of the spongy bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trabecular Number</measure>
    <time_frame>baseline versus two years</time_frame>
    <description>trabecular number done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Trabecular number is the number of individual pieces of the spongy bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical Porosity</measure>
    <time_frame>baseline versus two years</time_frame>
    <description>Cortical porosity done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Cortical Porosity measures how many tiny holes there are in the solid bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineralizing Surface</measure>
    <time_frame>baseline versus one year</time_frame>
    <description>Mineralizing surface done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Mineralizing surface measures how much of bone is getting new mineral put on it. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Hypoparathyroidism</condition>
  <arm_group>
    <arm_group_label>PTH(1-84)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mcg of PTH1-84 every other day, every day, or every three days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTH</intervention_name>
    <arm_group_label>PTH(1-84)</arm_group_label>
    <other_name>teriparatide</other_name>
    <other_name>Preotact</other_name>
    <other_name>PTH1-84</other_name>
    <other_name>rhPTH</other_name>
    <other_name>Natpara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypoparathyroidism

        Exclusion Criteria:

          -  Bisphosphonate use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Bilezikian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2007</study_first_submitted>
  <study_first_submitted_qc>May 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2007</study_first_posted>
  <results_first_submitted>October 23, 2013</results_first_submitted>
  <results_first_submitted_qc>July 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2015</results_first_posted>
  <last_update_submitted>July 14, 2015</last_update_submitted>
  <last_update_submitted_qc>July 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>John P. Bilezikian</investigator_full_name>
    <investigator_title>Dorothy L. and Daniel H. Silberberg Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>68 subjects were enrolled from 05/12/2004 to 06/19/2014 at Columbia University Medical Center.</recruitment_details>
      <pre_assignment_details>The first 6 participants in the study were randomly assigned to PTH1-84 100mcg daily, 100mcg every other day, and 100mcg every three days as a pilot project to determine the correct dosing regimen.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PTH1-84</title>
          <description>participants received PTH1-84 in either 100mcg daily, every other day, or every three days based on investigators clinical judgement</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unrelated adverse event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Off treatment early</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>hypoparathyroidism patients who signed Consent to participate in the study</population>
      <group_list>
        <group group_id="B1">
          <title>PTH1-84</title>
          <description>participants recieved PTH1-84 in either 100mcg daily, every other day, or every three days based on investigators clinical judgement</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Requirements for Calcium Supplementation</title>
        <description>Serum and urinary calcium levels maintained by change in requirements for calcium supplementation</description>
        <time_frame>2 years</time_frame>
        <population>Only the first 30 participants to complete 24 months in the study were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>PTH1-84</title>
            <description>participants recieved PTH1-84 in either 100mcg daily, every other day, or every three days based on investigators clinical judgement</description>
          </group>
        </group_list>
        <measure>
          <title>Requirements for Calcium Supplementation</title>
          <description>Serum and urinary calcium levels maintained by change in requirements for calcium supplementation</description>
          <population>Only the first 30 participants to complete 24 months in the study were analyzed</population>
          <units>grams per day of calcium supplementation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Starting requirements</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Requirements at month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in BMD From Baseline to 24 Months by DXA</title>
        <description>Bone Mineral Density (BMD) as measured by Dual-energy X-ray absorptiometry (DXA).</description>
        <time_frame>baseline versus 24 months</time_frame>
        <population>Only the first 30 participants who completed 24 months of the study were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>PTH1-84</title>
            <description>participants recieved PTH1-84 in either 100mcg daily, every other day, or every three days based on investigators clinical judgement</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in BMD From Baseline to 24 Months by DXA</title>
          <description>Bone Mineral Density (BMD) as measured by Dual-energy X-ray absorptiometry (DXA).</description>
          <population>Only the first 30 participants who completed 24 months of the study were analyzed</population>
          <units>percentage of change to BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lumbar Spine BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral Neck BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal 1/3 Radius BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trabecular Width</title>
        <description>Trabecular width was obtained from histomorphometric assessment of percutaneous iliac crest bone biopsy. Trabecular width is the thickness of individual pieces of the spongy bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.</description>
        <time_frame>baseline versus two years</time_frame>
        <population>Only 16 subjects had paired bone biopsies obtained at baseline and after 24 months of PTH(1-84) treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PTH1-84</title>
            <description>participants recieved PTH1-84 in either 100mcg daily, every other day, or every three days based on investigators clinical judgement</description>
          </group>
        </group_list>
        <measure>
          <title>Trabecular Width</title>
          <description>Trabecular width was obtained from histomorphometric assessment of percutaneous iliac crest bone biopsy. Trabecular width is the thickness of individual pieces of the spongy bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.</description>
          <population>Only 16 subjects had paired bone biopsies obtained at baseline and after 24 months of PTH(1-84) treatment.</population>
          <units>micrometers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trabecular Number</title>
        <description>trabecular number done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Trabecular number is the number of individual pieces of the spongy bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.</description>
        <time_frame>baseline versus two years</time_frame>
        <population>Only 16 subjects had paired bone biopsies obtained at baseline and after 24 months of PTH(1-84) treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PTH1-84</title>
            <description>participants recieved PTH1-84 in either 100mcg daily, every other day, or every three days based on investigators clinical judgement</description>
          </group>
        </group_list>
        <measure>
          <title>Trabecular Number</title>
          <description>trabecular number done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Trabecular number is the number of individual pieces of the spongy bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.</description>
          <population>Only 16 subjects had paired bone biopsies obtained at baseline and after 24 months of PTH(1-84) treatment.</population>
          <units>mm^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cortical Porosity</title>
        <description>Cortical porosity done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Cortical Porosity measures how many tiny holes there are in the solid bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.</description>
        <time_frame>baseline versus two years</time_frame>
        <population>Only 16 subjects had paired bone biopsies obtained at baseline and after 24 months of PTH(1-84) treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PTH1-84</title>
            <description>participants recieved PTH1-84 in either 100mcg daily, every other day, or every three days based on investigators clinical judgement</description>
          </group>
        </group_list>
        <measure>
          <title>Cortical Porosity</title>
          <description>Cortical porosity done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Cortical Porosity measures how many tiny holes there are in the solid bone section. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.</description>
          <population>Only 16 subjects had paired bone biopsies obtained at baseline and after 24 months of PTH(1-84) treatment.</population>
          <units>percentage of porosity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mineralizing Surface</title>
        <description>Mineralizing surface done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Mineralizing surface measures how much of bone is getting new mineral put on it. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.</description>
        <time_frame>baseline versus one year</time_frame>
        <population>Only 14 subjects had paird bone biopsies obtained at baseline and after 12 months of PTH(1-84) treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PTH1-84</title>
            <description>participants recieved PTH1-84 in either 100mcg daily, every other day, or every three days based on investigators clinical judgement</description>
          </group>
        </group_list>
        <measure>
          <title>Mineralizing Surface</title>
          <description>Mineralizing surface done on histomorphometric assessment of percutaneous iliac crest bone biopsy. Mineralizing surface measures how much of bone is getting new mineral put on it. The structure and microscopic organization of a small piece of biopsied pelvic bone was analyzed.</description>
          <population>Only 14 subjects had paird bone biopsies obtained at baseline and after 12 months of PTH(1-84) treatment.</population>
          <units>percentage of surface</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>earliest SAE report is 8/2/05 and latest SAE report is 6/19/09</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PTH1-84</title>
          <description>participants recieved PTH1-84 in either 100mcg daily, every other day, or every three days based on investigators clinical judgement</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <description>categorized as a Serious Adverse Event because it involved hospitalization. unrelated to study participation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <description>patient hospitalized with dehydration unrelated to study participation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Fainted</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Due to GERD</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>angina</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>categorized as an SAE because it involved hospitalization unlikely to be related to study participation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>symptomatic hypocalcemia</sub_title>
                <description>though hypocalcemia is an anticipated syndrome of hypoparathyroidism, this event resulted in hospitalization
unrelated to study participation</description>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>pancreatitis, accute</sub_title>
                <description>not related to study participation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ampullary mass</sub_title>
                <description>unrelated to study participation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection at bone biopsy site</sub_title>
                <description>secondary to participation in study but unrelated to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>categorized as an SAE because it involved hospitalization. unrelated to study participation</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>laryngeal spasm</sub_title>
                <description>categorized as an SAE because it involved hospitalization unrelated to study participation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>concussion</sub_title>
                <description>concussion secondary to car accident categorized as an SAE because it involved hospitalization unrelated to study participation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Right Kidney mass</sub_title>
                <description>unlikely to be related to study participation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>L Oophorectomy</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>categorized as a SAE because it involved hospitalization unrelated to study participation</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>damage to surgical site of recent hernia repair</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>patient fell and damaged the surgical site of a recent hernia repair categorized as an SAE because it involved hospitalization unrelated to study participation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>cyst removal</sub_title>
                <description>unrelated to study participation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Elective Surgery</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Body Swelling</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="29" subjects_affected="23" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Temperature Sensitivity</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Hypocalcemic Symptoms</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Opthalmological Irritability/Visual Impairment</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="47" subjects_affected="34" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold/Flu Virus/Symptoms</sub_title>
                <description>This adverse event refers to patients who had experienced either cold and flu virus's or symptoms</description>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="42" subjects_affected="29" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight Fluctuations</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="134" subjects_affected="47" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Irritability</sub_title>
                <counts group_id="E1" events="74" subjects_affected="41" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Bone Fracture</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cysts</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Headache/Migraine</sub_title>
                <counts group_id="E1" events="42" subjects_affected="32" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety/Irritabilty/Stress</sub_title>
                <counts group_id="E1" events="29" subjects_affected="20" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Confusion\Disorientation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease in Urination</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Increased Urination</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Increased Thirst</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Kidney Stone/Kidney Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Difficulty Breathing</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Rash locations vary from patient to patient, areas reported were face and cheeks, arms and legs and coccyx areas.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Bruising at injection site</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only 16 subjects received a bone biopsy, which is why many of the measurements were only analyzed in 16 subjects. In total, data was only analyzed for the first 30 subjects analyzed for data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John P. Bilezikian MD</name_or_title>
      <organization>Columbia University Medical Center</organization>
      <phone>212-305-2663</phone>
      <email>jpb2@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

